KR920702410A - 수정된 생물학적 물질 - Google Patents

수정된 생물학적 물질

Info

Publication number
KR920702410A
KR920702410A KR1019920700843A KR920700843A KR920702410A KR 920702410 A KR920702410 A KR 920702410A KR 1019920700843 A KR1019920700843 A KR 1019920700843A KR 920700843 A KR920700843 A KR 920700843A KR 920702410 A KR920702410 A KR 920702410A
Authority
KR
South Korea
Prior art keywords
species
receptor
hcrf
animal
tissue
Prior art date
Application number
KR1019920700843A
Other languages
English (en)
Inventor
제임스 그라함 화이트 데이비드
프레드릭 윌리암스 알란
Original Assignee
원본미기재
임뮤트란 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296038&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920702410(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898922987A external-priority patent/GB8922987D0/en
Priority claimed from GB909017198A external-priority patent/GB9017198D0/en
Application filed by 원본미기재, 임뮤트란 리미티드 filed Critical 원본미기재
Publication of KR920702410A publication Critical patent/KR920702410A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

수정된 생물학적 물질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제2도는 실시예 1에서 사용된 돼지들이 항종항체(antispecies antibody)를 가지고 있지 않다는 것을 나타내는 방사면역분석(radioimmunoassay)의 결과이다 ; 제6도는 실시예 5에서 사용한 크롬 방출세포용해분석법(chromium release cell lysis assay)의 결과를 나타낸다.

Claims (27)

  1. 수용체와 다른 종으로서, 수용체와 불일치하는(discordant)종인 공여체로부터 얻어진 동물조직을 수용체에 이식하고, 보체의 완전활성을 방지하기 위해 수용체종에 한개이상의 동종보체억제인자(HCRFS)를 이식장기와 연관하여 제공하는 것으로 구성된 동물조직을 수용체에 장기이식하는 방법.
  2. 제1항에 있어서, 조직(tissue)이 장기(organ)인 방법.
  3. 제2항에 있어서, 장기(organ)가 심장, 폐, 간장, 신장, 취장및 갑상샘인 방법.
  4. 제1항에 있어서, 조직이 혈액 및 조혈세포, 랑겔한스샘, 뇌세포 및 내분비기관 (endocrime organ)의 세포인 방법.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, HCRF가 고전적 보체활성화경로 및 부보체 활성화경로 모두에 공통적인 보체활성화 케스캐이드 중 어느 단계를 방해하는 방법.
  6. 제1항내지 제5항중 어느 한 항에 있어서, HCRF가 자연상의 HCRF인 방법.
  7. 제5항에 있어서, HCRF가 C3단계에서의 보체활성화를 조절하는 방법.
  8. 제7항에 있어서, HCRF가 I인자 (이미 C3b 불활성화제 또는 KAF로 알려져있음); H인자;C4 결합 단백질; DAF(CD55로서 알려져 있음);막보조인자 단백질(MCP;또한 CD46으로써 알려져 있으며 처음에는 gp45-70으로서 설명되었고 gp66/56으로서 더 많이 알려져 있음) CR1(C3b/C4b 리셉터 또는 CD35로서 알려져 있음); 및/ 또한 CR2(CD21, C3,dg 리셉터, 3d/EBV 리셉터 및 P140)이거나 이들의 활성을 가지는 방법.
  9. 제1항 내지 제8항중 어느 한항에 있어서 HCRF가 염색체 1의 q32위치에 염색체 지도작성되는 RCA(보체활성조절인자)부위에 유전자가 위치한 자연상의 HCRF인 방법.
  10. 제5항에 있어서 HCRF가 C3단계 및/또는 C9단계에서 보체활성을 조절하는 방법.
  11. 제10항에 있어서 HCRF가 C3bp (또한 HRF 또는 MIP로서 알려져 있음);P-18(또한 HRF -20, CD59 또는 MIRL로서 알려져 있음)또는 SP40.40이거나 이들의 활성을 가지고 있는 방법.
  12. 제1항 내지 제1항중 어느 한항에 있어서 HCRF가 막에 결합되어져 있는 방법.
  13. 제1항 내지 제12항중 어느 한 항에 있어서 HCRF가 공여체조직의 세포막에 걸합되어진 상태로 제공되는 방법.
  14. 제13항에 있어서, 수용체에 이식되었을때 수용체 종에서 활성을 띠는 한개 이상의 HCRFS를 코딩하는 핵산을 가지고 있으며 이들을 발현하는 공여조직이 트란스제닉한(transgenic)방법.
  15. 제1항 내지 제14항중 어느 한항에 있어서, 수용체 종이 사람인 방법.
  16. 제1항 내지 제15항중 어느 한항에 있어서 공여종이 돼지인 방법.
  17. 세포 또는 조직은 보체의 완전활성을 방지하기위해 수용체 종에서 활성을 띠는 한개이상의 동종 보체억제인자를 가지고 있고 공여체종은 수용체에 대하여 디스코던트한 종인 공여체종의 이식될 수 있는 동물세포 또는 조직.
  18. 적어도 한가지 디스코던트한 종의 면역계에 노출되거나 또는 장기이식을 하였을 때 이종이식편 거부반응을 일으키지 않는 이식될 수 있는 조직을 가지고 있는 트란스제제닉한 동물(transgenic animal).
  19. 수용체종으로 이식될 수 있는 조직을 제조함에 있어서 공여체종이 수용체종에 대하여 디스코던트한 종인 공여체종으로 부터 얻어진 동물조직 및 수용체 종에서 활성을 띄는 하나이상의 동종보체 억제인자의 사용.
  20. 다른종의 동종보체억제인자를 발현할 수 있는 세포를 가지는 트란스제닉한 동물.
  21. 동물세포에 대해 디스코던트한 종에서 활성화되는 한개이상의 동종보체억제인자를 발현할 수 있는 비형질전환 동물세포 (non-transformed animal cell).
  22. 적어도 한개의 동종보체억제인자를 코팅하는 DNA와 이들 코딩 DNA가 비형질전화세포에 의해 발현되어지도록 할 수 있는 한개 이상의 염기서열로 구성된 제조합 DNA.
  23. 제22항에 있어서 동물세포가 유전조작물을 유전적으로 통합된 트란스제닉한 동물의 세포인 DNA.
  24. 제22항에 있어서, 세포가 랑겔한스샘과 같은 배양된 기관 또는 다른 조직으로된 DNA.
  25. 적어도 한개의 동종 보체억제인자를 코딩하는 DNA와 유전조작물이 유전적으로 통합된 트란스제닉한 동물의 적어도 어떤 세포에서 그 코딩 DNA가 발현될 수 있도록 하는 한개 이상의 염기서열로 구성된 유전조작물로서의 트란스제닉한 동물을 만들기위해 동물의 유전물질로 통합되기에 적합한 유전조작물.
  26. 제25항에 있어서, YAC의 형태를 가지는 유전 조작물.
  27. 적어도 한개의 동종보체억제인자를 코딩하는 DNA와 코딩 DNA가 트란스제닉한 동물의 적어도 어떤 세포에서 발혈될수 있도록 하는 한개 이상의 염기서열을 가지는 DNA를 동물의 유전물질로 통합시키는 것으로 구성된 트란스제닉한 동물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700843A 1989-10-12 1990-10-12 수정된 생물학적 물질 KR920702410A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB898922987A GB8922987D0 (en) 1989-10-12 1989-10-12 Modified biological material
GB89229878 1989-10-12
GB909017198A GB9017198D0 (en) 1990-08-06 1990-08-06 Modified biological material
GB90171984 1990-08-06
PCT/GB1990/001575 WO1991005855A1 (en) 1989-10-12 1990-10-12 Modified biological material

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019997005897A Division KR100317106B1 (ko) 1989-10-12 1990-10-12 수정된 생물학적 물질

Publications (1)

Publication Number Publication Date
KR920702410A true KR920702410A (ko) 1992-09-04

Family

ID=26296038

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019920700843A KR920702410A (ko) 1989-10-12 1990-10-12 수정된 생물학적 물질
KR1019997005897A KR100317106B1 (ko) 1989-10-12 1990-10-12 수정된 생물학적 물질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019997005897A KR100317106B1 (ko) 1989-10-12 1990-10-12 수정된 생물학적 물질

Country Status (27)

Country Link
US (1) US6495735B1 (ko)
EP (2) EP0709459A3 (ko)
JP (1) JP3302358B2 (ko)
KR (2) KR920702410A (ko)
CN (2) CN1122719C (ko)
AT (1) ATE139562T1 (ko)
AU (1) AU654116B2 (ko)
BG (1) BG61080B1 (ko)
CA (1) CA2067235A1 (ko)
CY (1) CY1996A (ko)
DE (2) DE69027535T2 (ko)
DK (1) DK0495852T3 (ko)
ES (1) ES2060561T3 (ko)
FI (1) FI921618A0 (ko)
GR (2) GR940300004T1 (ko)
HK (1) HK48497A (ko)
HU (1) HUT64584A (ko)
IE (1) IE75345B1 (ko)
IL (2) IL95970A0 (ko)
IN (1) IN171948B (ko)
MY (1) MY107433A (ko)
NO (2) NO303502B1 (ko)
NZ (2) NZ235657A (ko)
PT (2) PT95580B (ko)
RO (1) RO109863B1 (ko)
SG (1) SG72614A1 (ko)
WO (1) WO1991005855A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
JP2750220B2 (ja) * 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
DE69133111D1 (de) * 1990-05-11 2002-10-24 Austin Res Inst Heidelberg CD46 Isoformen
US5846715A (en) * 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
JPH06506604A (ja) * 1991-07-15 1994-07-28 オクラホマ メディカル リサーチ ファウンデーション 自在なドナー細胞
US6916654B1 (en) * 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
EP0662125A1 (en) * 1992-09-22 1995-07-12 Dnx Biotherapeutics, Inc. Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
CA2196311A1 (en) * 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
CA2227584A1 (en) 1995-08-04 1997-02-20 The General Hospital Corporation Transgenic swine and swine cells having human hla genes
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
WO1997035886A1 (en) * 1996-03-22 1997-10-02 Imutran Limited Surfaces which prevent or reduce complement activation
DE69833545T2 (de) 1997-03-26 2006-12-14 Imperial College Innovations Ltd. In der zellmembran verankertes antikoagulant-fusionsprotein
ATE313256T1 (de) 1997-07-14 2006-01-15 Nippon Meat Packers Transgene schweine
US7419683B2 (en) * 1997-10-31 2008-09-02 United States Of America As Represented By The Secretary Of The Army Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
SE523817C2 (sv) * 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
EP1651050B1 (en) * 2003-07-21 2012-08-22 Lifecell Corporation Acellular tissue matrices made from galactose alpha-1,3-galactose -deficient tissue
CA3104704A1 (en) 2009-08-14 2011-02-17 Revivicor, Inc. Multi-transgenic pigs for diabetes treatment
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
EP2675901B1 (en) 2011-02-14 2018-05-30 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
AU2014341866B2 (en) 2013-11-04 2018-07-05 Lifecell Corporation Methods of removing alpha-galactose
CN114686427B (zh) * 2022-05-23 2022-07-29 中国人民解放军总医院第一医学中心 一种脾脏调节型b淋巴细胞及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982004443A1 (en) * 1981-06-12 1982-12-23 Ohio Univ Genetic transformation of zygotes
US4431636A (en) 1982-05-24 1984-02-14 American Cyanamid Company Bis(4-O-polyhexaose-thio)-phenyl ureas and method of use
US5109113A (en) * 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
JPS62104594A (ja) * 1985-10-31 1987-05-15 Terumo Corp クエン酸塩利用能検査用培地組成物
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
IL82390A0 (en) * 1986-05-02 1987-10-30 Genentech Inc Nucleic acid and methods for the synthesis of novel daf compositions
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59

Also Published As

Publication number Publication date
PT101896B (pt) 2003-01-31
FI921618A (fi) 1992-04-10
DK0495852T3 (da) 1996-07-15
CN1051199A (zh) 1991-05-08
DE495852T1 (de) 1994-03-31
DE69027535T2 (de) 1996-11-28
EP0709459A2 (en) 1996-05-01
DE69027535D1 (de) 1996-07-25
EP0495852A1 (en) 1992-07-29
CN1122719C (zh) 2003-10-01
NO982131L (no) 1992-04-10
NZ248153A (en) 1997-07-27
CN1491624A (zh) 2004-04-28
IL95970A0 (en) 1992-05-25
PT95580A (pt) 1991-09-13
JP3302358B2 (ja) 2002-07-15
JPH05503074A (ja) 1993-05-27
EP0709459A3 (en) 1999-01-07
HUT64584A (en) 1994-01-28
CY1996A (en) 1997-09-05
ES2060561T1 (es) 1994-12-01
HK48497A (en) 1997-04-25
GR3020741T3 (en) 1996-11-30
BG61080B1 (bg) 1996-10-31
SG72614A1 (en) 2000-05-23
PT101896A (pt) 1998-02-27
IL120795A0 (en) 1997-09-30
KR100317106B1 (ko) 2001-12-22
NO982131D0 (no) 1998-05-11
EP0495852B1 (en) 1996-06-19
ES2060561T3 (es) 1996-08-01
CA2067235A1 (en) 1991-04-13
RO109863B1 (ro) 1995-06-30
NO303502B1 (no) 1998-07-20
IN171948B (ko) 1993-02-13
FI921618A0 (fi) 1992-04-10
BG96329A (bg) 1993-12-24
ATE139562T1 (de) 1996-07-15
NO921438D0 (no) 1992-04-10
HU9201240D0 (en) 1992-06-29
NZ235657A (en) 1994-05-26
AU6539290A (en) 1991-05-16
AU654116B2 (en) 1994-10-27
GR940300004T1 (en) 1994-02-28
MY107433A (en) 1995-12-30
IE75345B1 (en) 1997-08-27
IE903649A1 (en) 1991-04-24
US6495735B1 (en) 2002-12-17
NO921438L (no) 1992-04-10
PT95580B (pt) 1999-05-31
WO1991005855A1 (en) 1991-05-02

Similar Documents

Publication Publication Date Title
KR920702410A (ko) 수정된 생물학적 물질
Ponder et al. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation.
Rosen et al. Regulation of milk protein gene expression
Hauser et al. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice
Rittling et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro
TJÄLVE et al. Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets
WO2014066505A1 (en) Double knockout (gt/cmah-ko) pigs, organs and tissues
Krüger et al. Sp1/Sp3 compound heterozygous mice are not viable: impaired erythropoiesis and severe placental defects
Mueller et al. Immediate and persistent effects of temperature on oxygen consumption and thermal tolerance in embryos and larvae of the Baja California chorus frog, Pseudacris hypochondriaca
Yamamoto et al. Systemic silencing of PHD2 causes reversible immune regulatory dysfunction
Wang et al. Transgenic expression of human cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) by porcine skin for xenogeneic skin grafting
Chen et al. Elimination of donor CD47 protects against vascularized allograft rejection in mice
Yannoutsos et al. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection
JP2020535834A (ja) 遺伝子修飾されたベータ細胞による糖尿病の治療
Xu et al. Germ cell-less hybrid fish: ideal recipient for spermatogonial transplantation for the rapid production of donor-derived sperm
US6927060B2 (en) Methods to prepare and use epidermal stem cells
Smolenski et al. Reduction of hyperacute rejection and protection of metabolism and function in hearts of human decay accelerating factor (hDAF)-expressing pigs
Roch Leukocyte DNA-synthesis in grafted lumbricids: An approach to study histocompatibility in invertebrates
JP2021511801A (ja) ブタ異種抗原の同定
WANG et al. Presence of Human Chromosome 1 with Expression of Human Decay‐Accelerating Factor (DAF) Prevents Lysis of Mouse/Human Hybrid Cells by Human Complement
Martin et al. Successful xenogeneic transplantation in embryos: induction of tolerance by extrathymic chick tissue grafted into quail
AU7935598A (en) Transgenic mammals
Sandstrom The growth and differentiation of duck kidney tissue on the chorio-allantoic membrane of the chick and duck
Nakahara et al. Generation of a T lx1 C re ER‐V enus knock‐in mouse strain for the study of spleen development
Even et al. After migration into blood circulation, hematopoietic stem cells can stably self-renew and maintain bone marrow while being skewed toward myeloid lineage when submitted to serial transplantation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
A107 Divisional application of patent
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19990528

Effective date: 20000531

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20000720

Effective date: 20010726

WITB Written withdrawal of application